دورية أكاديمية
Incremental cost burden among patients with severe uncontrolled asthma in the United States.
| العنوان: | Incremental cost burden among patients with severe uncontrolled asthma in the United States. |
|---|---|
| المؤلفون: | Burnette A; Division of Allergy and Immunology, Howard University, Washington, DC., Wang Y; Amgen Inc., Thousand Oaks, CA., Rane PB; Amgen Inc., Thousand Oaks, CA., Chung Y; AstraZeneca, Wilmington, DE., Princic N; Merative, Ann Arbor, MI., Park J; Merative, Ann Arbor, MI., Llanos JP; Amgen Inc., Thousand Oaks, CA., Lindsley AW; Amgen Inc., Thousand Oaks, CA., Ambrose CS; AstraZeneca, Wilmington, DE. |
| المصدر: | Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Jul; Vol. 29 (7), pp. 825-834. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : Academy of Managed Care Pharmacy, [2014]- |
| مواضيع طبية MeSH: | Asthma*/drug therapy , Asthma*/economics , Patient Acceptance of Health Care*/statistics & numerical data, Adult ; Humans ; Health Care Costs ; Retrospective Studies ; United States |
| مستخلص: | BACKGROUND: The economic burden of severe asthma and severe uncontrolled asthma (SUA) is significant. Updated assessments of health care resource utilization (HCRU) and cost are needed given the increase in treatment options and updates to guidelines in recent years. OBJECTIVE: To describe all-cause and asthma-related HCRU and costs among patients with SUA vs patients with nonsevere asthma in the United States using real-world data. METHODS: MarketScan administrative claims databases were used to select adults with persistent asthma for this retrospective analysis between January 1, 2013, and December 31, 2019. Asthma severity status was defined using the Global Initiative for Asthma step 4/5 criteria (index is the earliest date qualifying patients as severe or randomly assigned for nonsevere patients). Patients with SUA were a subset of the severe cohort meeting the following criteria: those who were hospitalized with asthma as the primary diagnosis or had at least 2 emergency department or outpatient visits with an asthma diagnosis and a steroid burst within 7 days. HCRU, costs (allcause and asthma-related defined as medical claims with an asthma diagnosis and pharmacy claims for asthma treatment), work loss, and indirect costs due to absenteeism and short-term disability (STD) were compared between patients with SUA, severe, and nonsevere asthma. Outcomes were reported during a fixed 12-month post-index period using chi-square and t-tests where appropriate. RESULTS: 533,172 patients with persistent asthma were identified (41.9% [223,610]) severe and 58.1% [309,562] nonsevere). Of the severe patients, 17.6% (39,380) had SUA. The mean (SD) all-cause total health care costs were significantly higher in patients with SUA ($23,353 [$40,817]) and severe asthma ($18,554 [$36,147]) compared with those with nonsevere asthma ($16,177 [$37,897], P < 0.001 vs nonsevere asthma). The results were consistent for asthma-related costs. In addition, although patients with severe asthma made up 41.9% of the total study population, they contributed disproportionately higher costs (60.5%) to the total asthma-related direct costs, with the effect more evident among patients with SUA (7.4% of study population contributed 17.7% of the total asthma-related costs). For the subset of patients with asthma with workplace absenteeism, patients with SUA lost more time from work (259.3 vs 236.2 hours lost, P = 0.002; 7.8 vs 5.3 STD days, P < 0.001), and had higher corresponding indirect costs ($5,944 vs $5,415, P = 0.002 for absenteeism related; $856 vs $582, P < 0.001 for STD related) compared with patients with nonsevere asthma. CONCLUSIONS: Patients with SUA have significantly higher asthma-related economic burden compared with patients with nonsevere asthma and contribute a disproportionally higher percentage of asthma-related costs. DISCLOSURES: This study was funded by Amgen and AstraZeneca. The design and analysis for this study was conducted primarily by Merative. Amgen and AstraZeneca provided funding to support protocol development, data analysis, and manuscript development activities associated with this study. Dr Burnette is on the advisory board and a consultant for GSK, a consultant and member of the advisory boards and speakers' bureaus of Sanofi, Genzyme, Regeneron, AstraZeneca, and Amgen Inc. Dr Wang, Dr Rane, Dr Lindsley, and Dr Llanos are employees and shareholders of Amgen Inc. Dr Chung and Dr Ambrose are employees and shareholders of AstraZeneca. Ms Princic and Ms Park are employees of Merative, which received funding from Amgen to conduct this study. |
| References: | Ann Am Thorac Soc. 2018 Mar;15(3):348-356. (PMID: 29323930) J Clin Epidemiol. 1992 Jun;45(6):613-9. (PMID: 1607900) Ann Allergy Asthma Immunol. 2019 Dec;123(6):564-572.e3. (PMID: 31494235) Curr Med Res Opin. 2018 Dec;34(12):2075-2088. (PMID: 30047292) Asthma Res Pract. 2017 Jan 6;3:1. (PMID: 28078100) Eur Respir J. 2014 Feb;43(2):343-73. (PMID: 24337046) Am J Respir Crit Care Med. 2019 Nov 1;200(9):1102-1112. (PMID: 31166782) Front Pediatr. 2019 Jun 18;7:246. (PMID: 31275909) J Manag Care Spec Pharm. 2016 Jul;22(7):848-61. (PMID: 27348285) J Asthma Allergy. 2020 Oct 29;13:545-555. (PMID: 33149626) J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):120-9.e3. (PMID: 26439182) |
| تواريخ الأحداث: | Date Created: 20230705 Date Completed: 20240205 Latest Revision: 20240205 |
| رمز التحديث: | 20240205 |
| مُعرف محوري في PubMed: | PMC10387979 |
| DOI: | 10.18553/jmcp.2023.29.7.825 |
| PMID: | 37404066 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2376-1032 |
|---|---|
| DOI: | 10.18553/jmcp.2023.29.7.825 |